WallStreetZenWallStreetZen

NASDAQ: ABSI
Absci Corp Stock Forecast, Predictions & Price Target

Analyst price target for ABSI

Based on 2 analysts offering 12 month price targets for Absci Corp.
Min Forecast
$5.00+1.63%
Avg Forecast
$6.00+21.95%
Max Forecast
$7.00+42.28%

Should I buy or sell ABSI stock?

Based on 2 analysts offering ratings for Absci Corp.
Strong Buy
Strong Buy
1 analysts 50%
Buy
1 analysts 50%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their ABSI stock forecasts and price targets.

ABSI stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-01-08
lockedlocked$00.00+00.00%2024-01-05

1 of 1

Forecast return on equity

Is ABSI forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
35.69%

Forecast return on assets

Is ABSI forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

ABSI revenue forecast

What is ABSI's revenue in the next 3 years based on estimates from 5 analysts?
Avg 1 year Forecast
$21.4M+208.2%
Avg 2 year Forecast
$39.2M+464.78%
Avg 3 year Forecast
$59.3M+755.1%
ABSI's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

ABSI revenue growth forecast

How is ABSI forecast to perform vs Biotechnology companies and vs the US market?
Company
103.7%
Industry
53.39%
Market
11.2%
ABSI's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
ABSI's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

ABSI vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ABSI$4.92$6.00+21.95%Strong Buy
TSHA$2.45$5.75+134.69%Strong Buy
TRDA$13.65$21.00+53.85%Buy
GHRS$8.72$40.00+358.72%Buy
AEON$12.12N/AN/A

Absci Stock Forecast FAQ

Is Absci Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: ABSI) stock is to Strong Buy ABSI stock.

Out of 2 analysts, 1 (50%) are recommending ABSI as a Strong Buy, 1 (50%) are recommending ABSI as a Buy, 0 (0%) are recommending ABSI as a Hold, 0 (0%) are recommending ABSI as a Sell, and 0 (0%) are recommending ABSI as a Strong Sell.

If you're new to stock investing, here's how to buy Absci stock.

What is ABSI's revenue growth forecast for 2024-2026?

(NASDAQ: ABSI) Absci's forecast annual revenue growth rate of 103.7% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 53.39%, and it is also forecast to beat the US market's average forecast revenue growth rate of 11.2%.

Absci's revenue in 2024 is $6,937,000.On average, 5 Wall Street analysts forecast ABSI's revenue for 2024 to be $1,987,024,638, with the lowest ABSI revenue forecast at $1,579,954,109, and the highest ABSI revenue forecast at $2,416,400,402. On average, 4 Wall Street analysts forecast ABSI's revenue for 2025 to be $3,641,236,590, with the lowest ABSI revenue forecast at $2,788,154,310, and the highest ABSI revenue forecast at $5,057,340,164.

In 2026, ABSI is forecast to generate $5,512,924,579 in revenue, with the lowest revenue forecast at $4,553,985,373 and the highest revenue forecast at $6,471,956,723.

What is ABSI's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: ABSI) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is ABSI's Price Target?

According to 2 Wall Street analysts that have issued a 1 year ABSI price target, the average ABSI price target is $6.00, with the highest ABSI stock price forecast at $7.00 and the lowest ABSI stock price forecast at $5.00.

On average, Wall Street analysts predict that Absci's share price could reach $6.00 by Jan 8, 2025. The average Absci stock price prediction forecasts a potential upside of 21.95% from the current ABSI share price of $4.92.

What is ABSI's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: ABSI) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.